FINWIRES · TerminalLIVE
FINWIRES

UnitedHealth's 'Favorable' Q2 Setup Driven by Improving Medical Cost Trends, BofA Says

By

UnitedHealth's (UNH) "favorable" Q2 earnings setup and attractive risk/reward are driven by improving medical cost trends and supportive near-term data points, BofA Securities said in a Thursday research report.

BofA said it now expects EPS for 2026, 2027, and 2028 of $18.70, $21, and $24, respectively, from $18.30, $20.17, and $22.34 earlier.

The company is guiding to the low-end of target margins by 2028, but even then, it would be well-positioned to grow earnings by at least 13% to 16% in the coming years, given that Optum Health and Medicaid would have room to lift margins back to the midpoint of target, analysts wrote.

While the company's benefit cuts this year make it difficult to perform well, its contracts remain relatively diversified, according to the note.

The brokerage said it upgraded the stock to buy from neutral and boosted its price target to $450 from $420.

Price: $399.43, Change: $+22.43, Percent Change: +5.95%

Related Articles

Wire

Erasca Sees More Balanced Outlook as Early RAS Data Support Clinical Activity, BofA Says

Erasca's (ERAS) early pan-RAS data have shifted the focus from whether ERAS-0015 is active to its potential commercial impact, with recent clinical results and stronger key opinion leader feedback strengthening confidence in the program's activity profile, BofA Securities said in a Thursday note.The analyst said ERAS-0015 has shown clinically meaningful activity across non-small cell lung cancer, pancreatic, and colorectal cancers, supporting Erasca's position in the competitive RAS-targeted therapy space, with safety appearing manageable so far but longer follow-up needed to confirm durability and survival benefit.BofA highlighted ERAS-4001 as a key pipeline opportunity in the second half of 2026 if it shows a broader therapeutic window and improved tolerability, while also citing colorectal cancer combinations and upcoming clinical readouts as near-term catalysts for sentiment and valuation.The outlook is now more balanced after early data, with upside from further efficacy confirmation, combinations, and readouts, while risks include durability, safety, competition, and uncertainty around differentiation and market path, the report added.BofA raised its rating on the stock to neutral from underperform and increased its price target to $16 from $9.Shares of Erasca were up 2.9% in Thursday trading.Price: $13.49, Change: $+0.31, Percent Change: +2.35%

$ERAS
Wire

Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case

Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case

$AMRN
Wire

Solaris Energy Infrastructure Set to Expand Capacity Despite Supply Chain Concerns, Morgan Stanley Says

Solaris Energy Infrastructure (SEI) is expected to continue to expand capacity despite facing a tight supply chain in the near term, Morgan Stanley analysts said in a Thursday note.Analysts said that the company will reach 3.2 gigawatts delivered by 2029, with roughly 1 gigawatt under shorter-term contracts or available for new contracts.Morgan Stanley said that Solaris' three long-term contracts with hyperscalers significantly enhance its credit profile and improve financial flexibility.Analysts said that Solaris' Q3 guidance is "conservative" and expects the company to beat it.Morgan Stanley retained an overweight rating on the stock and increased its price target to $90 from $81.Price: $74.61, Change: $+0.41, Percent Change: +0.55%

$SEI